RxDoctor Payments Data

Jacqueline Ferrari, NP

Adult Health · Newburyport, MANPI 1831572213

Payments from drug & device makers

$2,210in general payments, 2019–2025

Across 118 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$866
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$521
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • Takeda Pharmaceuticals U.S.A., Inc.$155
  • AstraZeneca$104
  • Gilead$90
  • plus $301 from 7 others

What the payments were for

  • Food & beverage$2,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,210 in reported general payments places this provider in the 85th percentile of 671 adult health providers in Massachusetts.

See all adult health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$49,458
Medicare patients
288
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide151$158,184
XifaxanRifaximin29$64,978
CreonLipase/Protease/Amylase56$60,190
TrulancePlecanatide50$37,775
VemlidyTenofovir Alafenamide21$33,324
MotegrityPrucalopride Succinate44$23,946
Mesalamine25$14,697
Omeprazole384$6,157
Entecavir13$4,030
PentasaMesalamine11$4,006
Famotidine167$3,159
Lubiprostone13$2,326
Esomeprazole Magnesium39$2,132
Pantoprazole Sodium149$2,014
Sucralfate16$1,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$866$218,373207 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$521$102,75379 claims
GileadVemlidy$90$33,32421 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$155$23,94644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 671 adult health providers in Massachusetts.

Other adult health in Newburyport

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →